All In Biotech

Drug Trial Radar · NCT04148391

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

Last checked: Nov 19, 2026Latest source record: Oct 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

99

Actual

Start

Nov 14, 2019

Primary completion

Dec 30, 2022

Study completion Dec 30, 2022

Sponsor

Lead sponsor
AptinyxIndustry
Sponsor type
Industry
Collaborators
CogState Ltd.; Worldwide Clinical Trials
First posted
Nov 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

Conditions

  • Mild Cognitive Impairment
  • Mild Dementia
  • Parkinson Disease
  • Lewy Body Disease

Interventions

  • Placebo Oral CapsuleDrug

    Matching placebo capsules.

  • NYX-458Drug

    NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in physical examinationTime frame: Subjects will be followed up to 14 days post-dose
  2. Rates of adverse events and serious adverse eventsTime frame: Subjects will be followed up to 14 days post-dose
  3. Rates of early termination due to adverse eventsTime frame: Subjects will be followed up to 14 days post-dose
  4. Change from baseline in vital signs, clinical laboratory values, and electrocardiogram resultsTime frame: Subjects will be followed up to 14 days post-dose
  5. Change from baseline dissociative effects, psychosis, and hallucinatory symptoms as measured by the Neuropsychiatric Inventory (NPI-12)Time frame: Subjects will be followed up to 14 days post-dose
  6. Change from baseline in suicidal ideation and behavior as measured by the Sheehan Suicidality Tracking Scale (S-STS)Time frame: Subjects will be followed up to 14 days post-dose
  7. Change from baseline in motor complications as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 4Time frame: Subjects will be followed up to 14 days post-dose
  8. Change in total score of the Sheehan Suicidality Tracking Scale (S-STS)Time frame: Subjects will be followed up to 14 days post-dose

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Aptinyx Clinical Site

    Scottsdale, Arizona

  • Aptinyx Clinical Site

    Fresno, California

  • Aptinyx Clinical Site

    Simi Valley, California

  • Aptinyx Clinical Site

    Boca Raton, Florida

  • Aptinyx Clinical Site

    Bradenton, Florida

  • Aptinyx Clinical Site

    Miami, Florida

  • Aptinyx Clinical Site

    Miami, Florida

  • Aptinyx Clinical Site

    Miami, Florida

  • Aptinyx Clinical Site

    Miami, Florida

  • Aptinyx Clinical Site

    Miami Lakes, Florida

  • Aptinyx Clinical Site

    Orlando, Florida

  • Aptinyx Clinical Site

    Port Charlotte, Florida

  • Aptinyx Clinical Site

    Port Orange, Florida

  • Aptinyx Clinical Site

    Sunrise, Florida

  • Aptinyx Clinical Site

    Decatur, Georgia

  • Aptinyx Clinical Site

    Farmington Hills, Michigan

  • Aptinyx Clinical Site

    Golden Valley, Minnesota

  • Aptinyx Clinical Site

    Toms River, New Jersey

  • Aptinyx Clinical Site

    Poughkeepsie, New York

  • Aptinyx Clinical Site

    Asheville, North Carolina

  • Aptinyx Clinical Site

    Dayton, Ohio

  • Aptinyx Clinical Site

    Tulsa, Oklahoma

  • Aptinyx Clinical Site

    Round Rock, Texas

  • Aptinyx Clinical Site

    Sugar Land, Texas

  • Aptinyx Clinical Site

    Bellevue, Washington

  • Aptinyx Clinical Site

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.